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Aims The aims of this study were to describe arrhythmias documented with an implantable loop recorder (ILR) in post-
acute myocardial infarction (AMI) patients with left ventricular dysfunction at the time of death and to establish the
correlation to mode of death.
Methods
and results
Post-mortem ILR device interrogations were analysed from patients dying in the CARISMA study. Mode of death was
classified by a modified CAST classification. Twenty-six patients died with an implanted ILR. Of these, 16 had an elec-
trocardiogram recorded at the time of death. Ventricular tachycardia (VT)/ventricular fibrillation (VF) was terminal
rhythm in eight patients and bradyarrhythmias were observed in another eight patients. Of the deaths with peri-
mortem recordings, seven were classified as sudden cardiac death (SCD). In six of these, VF was documented at
the time of death. Six monitored deaths were classified as non-SCD (NSCD) of which only two had recordings
of VT/VF, whereas four had bradyarrhythmias. All peri-mortem recordings in non-cardiac death (NCD) were
bradyarrhythmia.
Conclusion Long-term monitoring in a population of post-AMI patients with left ventricular ejection fraction 40% showed that
VT/VF and bradyarrhythmia each accounted for half of the recorded events at the time of death. The ILR confirmed
that ventricular tachyarrhythmias are associated primarily with SCD, whereas bradyarrhythmias and electromechani-
cal dissociation seems dominant in NSCD and NCD.
The study was registered at ClinicalTrials.gov: NCT00145119.
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Introduction
Survivors of an acute myocardial infarction (AMI) with subsequent
left ventricular dysfunction have a high mortality rate. The extent
of myocardial damage and reduction of cardiac function are
correlated to the risk of death.1–3 Approximately 10–15% die
within 1 year of the AMI and about half of the deaths classified as
cardiac are sudden.4–6 However, the fraction of patients who die
suddenly due to malignant arrhythmias and the classification of the
terminal arrhythmias have been debated.7,8 Differentiating the
exact mode of death has been limited by technical shortcomings
in documenting the heart rhythm immediately before death. Con-
tinuous long-term electrocardiographic (ECG) surveillance has not
been feasible in out-of-hospital patients. In-hospital- and short-term
out-of-hospital surveillance studies utilizing telemetry and Holter
monitoring show that 80% of peri-mortem heart rhythms are ven-
tricular tachyarrhythmias, whereas 20% are bradyarrhythmias in
sudden cardiac death (SCD).9–12 Post-mortem implantable cardio-
verter defibrillator (ICD) interrogations also indicate that the
majority of SCDs in patients with ischaemic heart disease and
reduced left ventricular function are caused by ventricular tachyar-
rhythmia.13–17 A typical event sequence is described for the
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terminal ventricular tachyarrhythmias in SCD.18 Ventricular tachy-
cardia, sometimes preceded by sinus tachycardia, deteriorates into
VF and ultimately into asystole. This course of events was confirmed
in ambulatory monitoring studies.9
Recently, the investigators of the Cardiac Arrhythmias and RIsk
Stratification after Myocardial infArction (CARISMA) study
reported the results of 2 years of continuous arrhythmia monitor-
ing in post-AMI patients using an implantable loop recorder
(ILR).19 The objectives were to assess the 2-year incidence of
arrhythmias after an AMI and estimate the predictive value of
several non-invasive and invasive tests regarding ICD preventable
ventricular tachycardia (VT)/ventricular fibrillation (VF). Holter-
derived measures of heart rate variability were found to be signifi-
cant predictors of VT/VF. The incidence of AV block was found to
be high and associated with an increased mortality rate. In this
study, the electrical activity of the heart at the time of death was
documented in patients dying with an ILR.
The purpose of the present study was to determine which
arrhythmias were observed at the time of death in different cat-
egories of mode of death. We analysed post-mortem ILR interro-
gations from the patients who died in the CARISMA study. Also,
we investigated the occurrence of rhythms preceding VF.
Methods
Patients
This substudy included all patients that died with an implanted ILR in
the CARISMA study.
Briefly, the CARISMA study included 312 patients with an AMI and a
subsequent left ventricular ejection fraction (LVEF) ,40% estimated
by 2D echocardiography.19 An ILR (Medtronic Revealw Plus) was
implanted 5–21 days after the AMI in 297 of these patients for con-
tinuous arrhythmia monitoring. The patients underwent a vast series
of risk stratification tests (12-lead ECG, 24 h Holter monitoring,
signal-averaged ECG, echocardiography, T-wave alternans, exercise
test, and an invasive electrophysiological study). Clinical follow-up
visits were scheduled quarterly for up to 2 years after the AMI.
The study was conducted in accordance with the declaration of Hel-
sinki and supplements hereof. All appropriate Ethics Review Boards
approved the study. Patients gave informed consent prior to inclusion.
Implantable loop recorder
The ILR recorded one bipolar lead and was programmed to automati-
cally record at pre-determined triggering events. Asystole was
detected as R-R interval .5 s, bradycardia as .4 beats with a fre-
quency ,30 min21 and tachycardia as .16 beats with a frequency
.125 min21. Electrocardiogram of automatic recordings contained
1 min before and after the triggering event. The ILR was able to
store 13 automatic events and also allowed storage of one manually
activated recording. Manual recordings were of 14 min length and
offered the opportunity to link the recording to patient symptoms at
the time of recording. The total device storage capacity was 42 min
of ECG. Explantation and interrogation was performed post-mortem
in patients who died during follow-up. Interrogation was performed
using a standard programmer (Medtronic 9790).
Mode of death
A modified CAST classification was applied to establish the mode of
death.20 Sudden cardiac death was defined as unexpected death
within 1 h of onset of symptoms or unexpected and unwitnessed
death within 24 h after the deceased was last seen alive. Deaths
were classified as non-SCD (NSCD) if the cause of death was
cardiac but did not meet SCD criteria. Death was presumed cardiac
if there were no specific evidence of non-cardiac death (NCD).
Cardiac death was presumed arrhythmic unless specific evidence
suggested otherwise. Resuscitated cardiac arrest was not considered
death. An endpoint committee reviewed the clinical information
preceding the death in each case and defined the mode of death.
Arrhythmias
The terminal cardiac rhythm was categorized as VT, VF, or bradyar-
rhythmia. If death occurred at a time where ECG showed any
other rhythm, this was interpreted as signal noise or non-classifiable
agonal rhythm.
Time of death
The time of death stated on the death certificate corresponding to the
time of clinical death was employed whenever available. Otherwise,
information about the clinical events surrounding the time of death
of the patient was retrieved from the medical record and compared
with the time of the ECG suspected to contain the terminal event.
Electrocardiogram recorded within 1 h of the derived time of death
was accepted as connected to the death. If exact time of death
could not be established from the above, the ILR recordings were
used to determine a likely time of death, e.g. when a patient died at
night at home and the ECG showed an event of VF during the night.
Statistics
Analysis of variance between patients in the three subgroups of mode
of death was performed using ANOVA and Fisher’s exact test for con-
tinuous and categorical variables, respectively. P-values of ,0.05 were
considered significant. Statistic analyses were done using SAS 9.1.3
(SAS Institute, Cary, NC, USA). The authors had full access to all
study data and performed the necessary analysis independent of the
sponsor.
Results
The characteristics of patients dying with an ILR are shown in
Table 1. Significant variance was found in subgroup analysis by
mode of death regarding clinical heart failure prior to inclusion
(P ¼ 0.02), NYHA class at discharge (P ¼ 0.02), and medication
status at the last follow-up visit including beta-blockers (P,
0.05), diuretics (P ¼ 0.005), and statins (P ¼ 0.04). The proportion
of patients with AMI prior to inclusion was also markedly higher in
the NSCD group than in patients of other modes of death.
During an average follow-up of 1.9+0.5 years, 36 of the 297
ILR patients died. The ILR was explanted before the time
of death in 10 patients due to coronary artery bypass grafting
(n ¼ 1), battery end-of-life (n ¼ 1), or implantation of either ICD
(n ¼ 6) or pacemaker (PM) (n ¼ 2). The remaining 26 patients
died with an implanted ILR (Table 2). Electrocardiogram was
recorded in 16 (62%) of these patients within 1 h of the time of
death. The time of death was derived from terminal event
ECG in three cases. Seven patients had no reliable recordings
at the time of death due to memory overwriting (n ¼ 3), PM
(n ¼ 1), time-stamping malfunction (n ¼ 1), and unknown
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reasons (n ¼ 2). In three instances, the device was not interrogated
post-mortem.
Ventricular fibrillation was observed in six SCDs and one NSCD
(Figure 1). Initiation of VF was visible in five instances. Ventricular
tachycardia did not precede VF in any of these. Monomorphic
VT was detected as terminal rhythm in one patient dying of
NSCD. Bradyarrhythmias were detected in one SCD, four
NSCDs, and three NCDs (Figure 2). In two of the patients dying
of NSCD, the peri-mortem recordings were of PM rhythm
(60 bpm). Underlying bradyarrhythmia and electromechanical dis-
sociation was assumed in these cases.
Of the 26 deaths with an implanted ILR, 19 were cardiac; 9 were
sudden and 10 were non-sudden. Electrocardiogram was available
at the time of death in 68% of the patients dying of cardiac causes.
Seven patients died from non-cardiac causes; septic shock (n ¼ 4),
advanced lung cancer (n ¼ 1), severe pneumonia (n ¼ 1), and
abdominal bleeding (n ¼ 1). Recordings were present in 43% of
the NCDs.
No significant differences were found in the ILR device settings
of sensibility and gain in patients dying without terminal event
recordings compared with the overall CARISMA population.
Analysis of the circadian variation at the time of death showed
that half of the patients dying with an ILR died at nighttime (0–
8 a.m.). There were no differences in mode of death in regard to
time of death.
Discussion
To determine which arrhythmias were observed at the time of
death in different categories of mode of death, we analysed
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Table 1 Characteristics of patients dying with an implanted ILR
Total,† n5 26 SCD, n 5 9 NSCD, n5 10 NCD, n 5 7
Demographics
Age (years) 70+11 69+11 69+14 73+7
GenderF (%) 69 89 70 43
BMI (kg/m2) 27.0+6.7 27.5+4.0 30.3+9.8 22.4+3.2
Smoking (%) 85 100 80 71
Medical history
Hypertension (%) 42 33 40 57
Diabetes (%) 31 33 40 14
Hypercholesterolaemia (%) 42 22 70 29
Renal disease (%) 12 11 20 0
Prior MI (%) 50 33 80 29
Clinical heart failure (%)† 27 11 50 14
NYHA class .I (%)† 88 100 100 57
LVEF (%) 31+5 31+6 31+6 32+4
Medication at last follow-up
Beta-blocker (%)† 81 89 90 57
Calcium channel antagonists (%) 12 0 20 14
ACE-I/AT-II antagonists (%) 77 89 80 57
Diuretics (%)† 81 89 100 43
Digoxin (%) 19 11 30 14
Statins (%)† 62 56 80 43
Clopidogrel (%) 38 44 40 29
Amiodarone (%) 4 0 0 14
†Two-sided P-value ,0.05.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Heart rhythm recorded within 1 h of death
Mode of death Ventricular fibrillation Ventricular tachycardia Bradyarrhythmia No rhythm No interrogation Total
SCD 6 – 1 1 1 9
NSCD 1 1 4 3 1 10
NCD – – 3 3 1 7
Total 7 1 8 7 3 26
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post-mortem ILR interrogations from the CARISMA study. The
major finding from these analyses was that the majority of
sudden deaths occurring in post-AMI patients with left ventricular
dysfunction are in fact due to VF. Previous studies assessing the
terminal rhythm at the time of sudden death have been based
on selected patient populations. Primarily, these included hospital-
ized patients with indications for Holter recording or telemetry
and patients with an implanted ICD in whom the device was not
able to prevent sudden death.9,21 In contrast, the ILR recordings
in patients dying of SCD in the CARISMA study represent peri-
mortem arrhythmia occurrences in patients without pre-existing
symptoms of arrhythmia or indications for ICD by contemporary
guidelines (which changed over the course of the study since
MADIT II came out in 2002 and the study was conducted from
2001 to 2006). Since the electrograms (EGM) of the terminal
events were blinded to the endpoint committee classifying the
mode of death, this observation shows that SCD defined by
common clinical criteria is indeed a result of ventricular tachyar-
rhythmia in the majority of patients dying suddenly after AMI.
This challenges conclusions from ICD studies suggesting that
Figure 1 Initiation of coarse VF in a patient dying of SCD.
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SCD defined by common methods is not frequently caused by
ventricular tachyarrhythmia.22 This controversial result may be
due to differences in patient characteristics. Also, the present
population represents post-AMI patients without a previously
documented life-threatening arrhythmia, whereas the ICD study
patients usually have a history of malignant arrhythmic events
and the ICD may have rescued them from an arrhythmic death
before their fatal event. The current data support the notion
that SCD among post-AMI patients may well serve as a surrogate
for ventricular tachyarrhythmia in clinical observational studies.
Bradyarrhythmia was terminal rhythm in only one patient in
whom death was defined as sudden. The ILR is currently mostly
acknowledged for its ability to detect bradyarrhythmias23,24 and
the proportion of ILR documented bradyarrhythmic sudden
deaths are in agreement with the results of previous studies.9–12
We also investigated the occurrence of rhythms preceding VF. In
contrast to the observations of Bayes de Luna et al.9 from Holter
recordings at the time of sudden death, VT did not precede VF in
any of the cases with sudden death in the present study. The
events were preceded by sinus rhythm or sinus tachycardia with
Figure 2 High-degree AV block in a patient dying of NSCD.
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ventricular premature beats in all EGMs with visible onset of VF.
This is also in contrast to experience from ICD recipients in
whom fast VTs treated by anti-tachycardia pacing are relatively
common.25,26 Again, the discrepant results most likely originate
from differences in the population characteristics.
The terminal rhythm was ventricular tachyarrhythmia only in
two cases defined as NSCD or NCD, again suggesting to a rela-
tively high specificity that ventricular tachyarrhythmia is primarily
associated to SCD. Of the NSCDs, 40% were due to progressive
heart failure and 50% were caused by terminal heart failure within
hours to days following a re-AMI. The data reported here are in
agreement with previous studies showing that the terminal
rhythm is often bradyarrhythmia leading to asystole among patients
with advanced heart failure.27
The comparison of patient characteristics in this substudy
revealed a few significant differences in administered medications
at the time of the last follow-up visit. Patients dying of cardiac
causes received beta-blockers and diuretics significantly more
often than those dying of non-cardiac causes. This is most likely
explained by the difference in NYHA class at discharge, the preva-
lence of prior AMI, and the significantly higher frequency of pre-
existing congestive heart failure among patients dying from
cardiac causes. Hypercholesterolaemia was found to be more fre-
quent in patients dying of NSCD and this probably accounts for
the difference in treatment with statins. We cannot exclude an
effect of these differences in medication on the mode of death
and the peri-mortem arrhythmias recorded. However, the
present study does not have the power of numbers to make any
such inferences.
The differences observed in the proportion of AMI and clinical
heart failure prior to inclusion are likely to have affected arrhyth-
mia substrates. Macro-re-entrant VT can potentially evolve encir-
cling areas of scared myocardium after AMI. However, since the
NSCD patients had the highest frequency of these characteristics,
this study indicates that if the prior AMI and heart failure had not
caused fatal arrhythmia before the time of inclusion, then bradyar-
rhythmias were the most probable arrhythmia at the time of death.
Limitations
Sample size
The sample size of the present study limited the number of deaths
with ILR recordings. Also, the ILR was explanted in 57 patients
receiving an ICD for primary (n ¼ 45) or secondary (n ¼ 12) pro-
phylaxis. Appropriate therapy (ATP/shock) for fast ventricular
tachyarrhythmias was delivered at least once in 11 patients by
their device. These patients might otherwise have died monitored
by their ILR. The low number of ILR-monitored deaths precludes
further elaboration on the precision of existing classifications of
mode of death.
The sample size also means that the statistical analyses are fragile
and must be interpreted with caution.
Technical limitations
Implantable loop recorder memory capacity was a limitation of
terminal event recording in three cases. Manual handling of the
deceased generated numerous signal noise recordings up to
4 days post-mortem. These artefact recordings may have overwrit-
ten recordings from the time of death.
This sensitivity makes it essential to explant the device as soon
as possible post-mortem in future studies. One missing recording
was possibly lost because of PM activity post-mortem preventing
the device from triggering EGM storage. This renders the ILR
unsuitable for bradyarrhythmia surveillance when other thera-
peutic devices are implanted.
General technical device limitations have already been discussed
elsewhere.28 Briefly, the ILR recordings are limited to arrhythmias
within the frequency spectrum of the algorithms, most likely
underestimating the occurrence. Furthermore, ST-segment devi-
ation analyses are not reliable from ILR EGM.
Conclusion
From long-term monitoring in a population of post-AMI patients
with LVEF 40% using an insertable loop recorder, we found
that VT/VF and bradyarrhythmia each accounted for 50% of
recorded events at the time of death. The ILR confirmed that ven-
tricular tachyarrhythmias are associated primarily with SCD,
whereas bradyarrhythmia and electromechanical dissociation
seems dominant in NSCD and NCD. Peri-mortem arrhythmias
were recorded in almost twice as many deaths classified as
cardiac as in deaths classified as non-cardiac.
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